Finally, molecular and cytogenetic abnormalities associated with conventional chemotherapy resistance, such as TP53 mutations, are common in patients with t-AML, leading to a poor prognosis [25, 26]. The gene discussed is TP53; the disease is acute myeloid leukemia.